Lumasiran (sodium)

Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) [1][2].

Product Specifications

CAS Number

[1834612-06-4]

UNSPSC

12352208

Target

Glycolate Oxidase; Small Interfering RNA (siRNA)

Type

Oligonucleotides

Related Pathways

Epigenetics; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lumasiran-sodium.html

Purity

99.21

Solubility

10 mM in H2O

Smiles

[Lumasiran(sodium)]

Molecular Formula

C530H668F10N173Na44O320P43S6

Molecular Weight

16340 (free acid)

References & Citations

[1]Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81 (2) :277-282.|[2]Garrelfs SF, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021 Apr 1;384 (13) :1216-1226.